Related Experiment Video
Updated: Jul 8, 2026
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Oncolytic measles virus strains in the treatment of gliomas
Cory Allen1, Georgia Paraskevakou, Chunsheng Liu
1Mayo Clinic, Molecular Medicine Department, 200 First Street SW, Rochester, MN 55905, USA.
Background:
Recurrent gliomas have a dismal outcome despite use of multimodality treatment including surgery, radiation therapy and chemotherapy.
Objective:
In this article the authors discuss potential applications of oncolytic measles virus strains as novel antitumor agents in the treatment of gliomas.
Methods:
Important aspects of measles virus development as an anticancer therapeutic agent including engineering, retargeting and combination studies with other therapeutic modalities are discussed. The translational process that led to the first clinical trial of an engineered measles virus derivative in patients with recurrent glioblastoma multiforme is also described.
Results/Conclusions:
Oncolytic measles virus strains hold promise as novel antitumor agents in the treatment of gliomas.
Insights
Oncolytic measles virus strains show promise for treating recurrent gliomas, a type of brain cancer with poor outcomes. Research is exploring their potential as novel antitumor agents in clinical trials.
Area of Science:
- Virology
- Oncology
- Gene Therapy
Background:
- Recurrent gliomas have a poor prognosis despite standard treatments like surgery, radiation, and chemotherapy.
- Glioblastoma multiforme is a particularly aggressive form of glioma with limited therapeutic options.
Purpose of the Study:
- To explore the potential of oncolytic measles virus strains as a novel therapeutic strategy for glioma treatment.
- To discuss the development and translational research of engineered measles virus for glioma therapy.
Main Methods:
- Engineering and retargeting of measles virus strains for enhanced antitumor activity.
- Combination studies of oncolytic measles virus with other therapeutic modalities.
- Description of the translational process leading to clinical trials in recurrent glioblastoma multiforme patients.
Main Results:
- Oncolytic measles virus strains demonstrate potential as anticancer agents.
- Engineered measles virus derivatives have progressed to clinical trials for recurrent glioblastoma.
Conclusions:
- Oncolytic measles virus represents a promising novel therapeutic approach for gliomas.
- Further clinical investigation is warranted to establish the efficacy of measles virus in glioma treatment.
